Porphyria Cutanea Tarda (Agent Orange)

Per General Rating Formula for the Skin (DCs 7806, 7809, 7813-7816, 7820-7822, and 7824), at least one of the following: Characteristic lesions involving more than 40 percent of the entire body or more than 40 percent of exposed areas affected; OR Constant or near-constant systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, psoralen with long-wave ultraviolet-A light (PUVA), or other immunosuppressive drugs required over the past 12-month period.

Per General Rating Formula for the Skin, at least one of the following: Characteristic lesions involving 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected; OR Systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period.

Per General Rating Formula for the Skin, at least one of the following: Characteristic lesions involving at least 5 percent, but less than 20 percent, of the entire body affected; OR At least 5 percent, but less than 20 percent, of exposed areas affected; OR Intermittent systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of less than 6 weeks over the past 12-month period.

Per General Rating Formula for the Skin: No more than topical therapy required over the past 12-month period and at least one of the following: Characteristic lesions involving less than 5 percent of the entire body affected; OR Characteristic lesions involving less than 5 percent of exposed areas affected. Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability.